Nicox AG
21.03.06 23:16
#1
_mo_
Nicox AG
Habe diese Firma vorher ins Hot - Stocks Forum gesetzt ; glaub aber da gehört sie nicht hin .
Ist ja kein Penny-Stock oder OTC BB Wert .
http://www.ariva.de/board/250158
Zum Chart ; die grüne Lienie muß sich noch als Unterstüzung heraus stellen . Im Intraday hat sie sich bewehrt bei 8,10 € . Morgen werden wir warscheinlisch die Tradingrange der neuen Fahne bestimmen . Das heutige Volumen entsprach 10 % der Gesamten Aktien .
21.03.06 23:18
#2
_mo_
Hier ein Chart wo man die Wiederstände heraus-
lesen kann .
Angehängte Grafik:
cox1.png (verkleinert auf 78%)
cox1.png (verkleinert auf 78%)
22.03.06 09:44
#3
_mo_
Die 8,10 halten wie ne 1
Kurz druntergetaucht ; aber da wird schön aufgesammelt und dann up
22.03.06 10:38
#5
_mo_
Bissi was zu lesen ?
CM-CIC Ups NicOx Target Price To EUR11.4
Tuesday, March 21, 2006 9:27:09 AM ET
Dow Jones Newswires
1314 GMT [Dow Jones] CM-CIC Securities ups NicOx's (7413.FR) target to EUR11.4 from EUR10.9, after the group signs an exclusive agreement with Merck (MRK) on the development of new antihypertensive drug. Says the importance of this agreement in terms of amount and the credibility of NicOx's research will lead to a continuation of the share's rerating which began early March with the announcement of the Pfizer (PFE) agreement. Reiterates at buy. Shares +27% at EUR8.49. (LAF)
INTERVIEW: NicOx Could Become A European Amgen - CEO
03-21-06 11:55 AM EST
PARIS -(Dow Jones)- The chief executive of NicOx SA (7413.FR) Tuesday said its osteoarthritis drug HCT 3012, in late stage of clinical development, could propel the French biotechnology company into the sector's top tier.
"If Phase III trial proves successful, NicOx could be a European Amgen," the company's chairman and chief executive officer Michele Garufi told Dow Jones Newswires, referring to Amgen Inc (AMGN), the world's largest biotechnology company.
Garufi said NicOx plans to have recruited by the beginning of the summer the 820 patients needed for its Phase III study which intends to confirm the drug's lack of interference with blood pressure. The company expects to yield results from the study in the fourth quarter of 2006.
Merck pulled Vioxx, its blockbuster arthritis drug, off the market in September 2004 after a study showed it doubled the risk of heart attacks and strokes after 18 months' use.
"HCT 3012 could potentially replace Vioxx and generate yearly sales of between EUR1 billion and EUR2 billion," Garufi said.
Earlier Tuesday the company announced a collaboration agreement with Merck & Co. on the development of new antihypertensive drugs using NicOx's nitric oxide- donating technology.
Under the terms of the agreement, NicOx will receive an upfront payment of EUR9.2 million and is eligible for potential further milestone payments of EUR279 million.
The news sent NicOx shares soaring. At 1630 GMTthey stood 26.8% higher on the day at EUR8.33 in a lower Paris market.
NicOx shares had already gained more than 80% since the beginning of the month, after it agreed to license the same nitric oxide-donating technology to Pfizer Inc. (PFE) for ophthalmology use in a deal that netted them EUR23 million up front and up to EUR300 million in milestones.
"Merck & Co probably does not wish to see the closer links between NicOx and Pfizer result in the latter becoming the preferred partner for a license agreement on HCT 3012, given its commercial potential as a pain killer with no secondary effects on hypertensions," CM-CIC analyst Francois Hamon said.
But Garufi said that since HCT 3012 is in late stage of development, NicOx is not at the moment desperately looking for a partner. "We have been approached but if we were to sign a collaboration agreement now, we would want to keep most of the marketing rights."
In 2005, NicOx posted a 442% rise in revenues to EUR6.5 million and increased its operational expenses by EUR7.0 million to EUR22.8 million.
The company told Dow Jones Newswires its 2006 revenues should rise by 23% to EUR8 million while operational expenses should increased by 31% to EUR30 million.
NicOx, which is 60% owned by US investors, said it currently has a net cash position of around EUR74 million, including the Merck and Pfizer agreements.
-By Laetitia Fontaine, Dow Jones Newswires; +33 (0)1 40 17 17 40; laetitia.fontaine@dowjones.com
(END) Dow Jones Newswires
03-21-06 1155ET
Copyright (c) 2006 Dow Jones & Company, Inc.
Tuesday, March 21, 2006 9:27:09 AM ET
Dow Jones Newswires
1314 GMT [Dow Jones] CM-CIC Securities ups NicOx's (7413.FR) target to EUR11.4 from EUR10.9, after the group signs an exclusive agreement with Merck (MRK) on the development of new antihypertensive drug. Says the importance of this agreement in terms of amount and the credibility of NicOx's research will lead to a continuation of the share's rerating which began early March with the announcement of the Pfizer (PFE) agreement. Reiterates at buy. Shares +27% at EUR8.49. (LAF)
INTERVIEW: NicOx Could Become A European Amgen - CEO
03-21-06 11:55 AM EST
PARIS -(Dow Jones)- The chief executive of NicOx SA (7413.FR) Tuesday said its osteoarthritis drug HCT 3012, in late stage of clinical development, could propel the French biotechnology company into the sector's top tier.
"If Phase III trial proves successful, NicOx could be a European Amgen," the company's chairman and chief executive officer Michele Garufi told Dow Jones Newswires, referring to Amgen Inc (AMGN), the world's largest biotechnology company.
Garufi said NicOx plans to have recruited by the beginning of the summer the 820 patients needed for its Phase III study which intends to confirm the drug's lack of interference with blood pressure. The company expects to yield results from the study in the fourth quarter of 2006.
Merck pulled Vioxx, its blockbuster arthritis drug, off the market in September 2004 after a study showed it doubled the risk of heart attacks and strokes after 18 months' use.
"HCT 3012 could potentially replace Vioxx and generate yearly sales of between EUR1 billion and EUR2 billion," Garufi said.
Earlier Tuesday the company announced a collaboration agreement with Merck & Co. on the development of new antihypertensive drugs using NicOx's nitric oxide- donating technology.
Under the terms of the agreement, NicOx will receive an upfront payment of EUR9.2 million and is eligible for potential further milestone payments of EUR279 million.
The news sent NicOx shares soaring. At 1630 GMTthey stood 26.8% higher on the day at EUR8.33 in a lower Paris market.
NicOx shares had already gained more than 80% since the beginning of the month, after it agreed to license the same nitric oxide-donating technology to Pfizer Inc. (PFE) for ophthalmology use in a deal that netted them EUR23 million up front and up to EUR300 million in milestones.
"Merck & Co probably does not wish to see the closer links between NicOx and Pfizer result in the latter becoming the preferred partner for a license agreement on HCT 3012, given its commercial potential as a pain killer with no secondary effects on hypertensions," CM-CIC analyst Francois Hamon said.
But Garufi said that since HCT 3012 is in late stage of development, NicOx is not at the moment desperately looking for a partner. "We have been approached but if we were to sign a collaboration agreement now, we would want to keep most of the marketing rights."
In 2005, NicOx posted a 442% rise in revenues to EUR6.5 million and increased its operational expenses by EUR7.0 million to EUR22.8 million.
The company told Dow Jones Newswires its 2006 revenues should rise by 23% to EUR8 million while operational expenses should increased by 31% to EUR30 million.
NicOx, which is 60% owned by US investors, said it currently has a net cash position of around EUR74 million, including the Merck and Pfizer agreements.
-By Laetitia Fontaine, Dow Jones Newswires; +33 (0)1 40 17 17 40; laetitia.fontaine@dowjones.com
(END) Dow Jones Newswires
03-21-06 1155ET
Copyright (c) 2006 Dow Jones & Company, Inc.
22.03.06 10:44
#6
_mo_
Wir haben eine neue Unterstützung bei 8,80
Ziel die 9 € brechen . Bollinger sagt bei 9,12 wäre schluß aber der hat sich schon 2 mal getäuscht und bekanntlich heißt es aller guten Dinge sind drei .
Gerade wurden die 9 € gebrochen 30000 aktien aus dem ask geklaut .
Gerade wurden die 9 € gebrochen 30000 aktien aus dem ask geklaut .
22.03.06 12:01
#7
_mo_
Intraday Chart o. T.
In frankfurt tut sich auch so langsam was .
Angehängte Grafik:
cox2.bmp
cox2.bmp
22.03.06 13:00
#10
_mo_
...
Steigt 9,15
| Nb | Qté | Achat | Vente | Qté | Nb |
| 4 | 1800 | ATP | 9.11 | 4703 | 4 |
| 6 | 3240 | 9.11 | 9.12 | 3015 | 8 |
| 2 | 9633 | 9.10 | 9.13 | 451 | 2 |
| 2 | 560 | 9.05 | 9.15 | 1215 | 5 |
| 1 | 682 | 9.00 | 9.16 | 650 | 3 |
| FMP |
22.03.06 13:41
#15
_mo_
alles was sich unter 9,50 ins ask setzt wird sofor
t aufgekauft - - - - > neue Unterstützung ?
22.03.06 13:57
#16
_mo_
20000 aus dem ask zwischen 6,68 - 7,72
Bid verschlingt alles was abgestossen wird .
22.03.06 14:17
#17
_mo_
Die Metzgerei ! RT Orderbuch
| Nb | Qté | Achat | Vente | Qté | Nb |
| 3 | 1070 | 9.53 | 9.62 | 120 | 1 |
| 1 | 3000 | 9.52 | 9.63 | 1030 | 3 |
| 4 | 1748 | 9.51 | 9.64 | 11000 | 2 |
| 11 | 145101 | 9.50 | 9.65 | 1258 | 2 |
| 2 | 1038 | 9.49 | 9.67 | 800 | 2 |
| FMP | - |
22.03.06 15:28
#18
_mo_
Sturtzflug bis auf GD 200 im Daily der müßte
halten . scheiß Amis .
Aber immer noch 12 % .
Aber immer noch 12 % .
23.03.06 18:06
#20
_mo_
Mit Gap geöffnet dann geschlossen und wieder up
Wiederstand bei 9,77
Unterstützung bei 9,20 und dann 8,80
Schlußkurs 9,46
Unterstützung bei 9,20 und dann 8,80
Schlußkurs 9,46
Angehängte Grafik:
nicox2.bmp
nicox2.bmp
Seite:
1